Fusix Biotech

Executive Summary

Fusix Biotech is a German biotechnology startup pioneering next-generation cancer immunotherapies using its proprietary InFUSE platform, an oncolytic virus technology designed to destroy tumors through direct oncolysis and immune stimulation. Founded in 2022 and based in Munich, the company collaborates closely with the Technical University of Munich. While still in early preclinical stages, Fusix's approach aims to address limitations in current oncolytic virus therapies by enhancing tumor selectivity and immune activation. The platform's versatility could enable combinations with checkpoint inhibitors and other immunotherapies. Despite limited publicly available data, the company's academic roots and novel technology position it as a potential player in the oncolytic virus space. Key risks include early-stage development uncertainty, lack of financing details, and competition from established oncolytic virus platforms. The next 12-18 months will be critical for demonstrating preclinical proof of concept and securing initial funding to advance towards clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Publication of preclinical in vivo efficacy data50% success
• Q4 2026Series A financing round40% success
• Q1 2027Research collaboration or license agreement with a larger pharma company30% success